Atul Kumar Mittal | Dr
Based on the available data, these drugs are great as adjunct OSA treatments, which include CPAP therapy for most patients. Tirzepatide significantly improved OSA outcomes, with concomitant reduction in body weight, compared with placebo in the SURMOUNT-OSA study
District Court for the Eastern District of Pennsylvania under the Honorable Karen Spencer Marston , this specialized docket handles all federal failure-to-warn lawsuits regarding GLP-1 vision loss
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly
From a regulatory and liability perspective, this is the only position a pharmaceutical manufacturer can reasonably take
Eric Topol (34:08): Yeah